---
title: "Metformin alters HMGA1a and RBM3 in breast cancer cells; ESR1 splicing effect varies with density"
id: "biorxiv-6-metformin-lowers-hmga1a-and-rbm3-protein-in-breast-cancer-cells-and-its-effect"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-6-metformin-lowers-hmga1a-and-rbm3-protein-in-breast-cancer-cells-and-its-effect"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.11.04.764423v1?rss=1"
published_at: "2026-11-05T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Metformin alters HMGA1a and RBM3 in breast cancer cells; ESR1 splicing effect varies with density
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-6-metformin-lowers-hmga1a-and-rbm3-protein-in-breast-cancer-cells-and-its-effect
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.11.04.764423v1?rss=1)
- **Published At:** 2026-11-05T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study examined how **metformin** affects ESR1 splicing and splicing-factor proteins in MCF-7 and tamoxifen-resistant TAMR1 breast cancer cells. - Metformin was tested across a dose range from 0.25 to 5 mM; outcomes differed by cell seeding density and exposure time. - At high seeding density, metformin produced no consistent dose-dependent change in the proportion of full-length **ESR1** transcript in either cell line; reported gel densitometry values varied (MCF-7: 42%, 43%, 42%, 43%, 45%, 48%; TAMR1: 55%, 44%, 52%, 47%, 68%, 43%). - At low density, the MCF-7 response persisted to 48 hours with full-length ESR1 shares reported as 52%, 62% and 68% at 0, 2.5 and 5 mM respectively. - Investigators measured protein levels and found **metformin** lowered **HMGA1a** in MCF-7 cells and showed a similar tendency in TAMR1 cells at both densities. - **RBM3** protein decreased in TAMR1 cells at 24 and 48 hours after metformin exposure; authors suggest RBM3 is a plausible mediator of splicing change based on this and prior knowledge. - The team previously linked HMGA1a to production of **ERα46** via U1 snRNP trapping; here a fall in HMGA1a would predict less ERα46, which does not match the TAMR1 low-density observation. - RT-PCR from earlier TAMR1 xenograft tumors detected full-length ESR1 in untreated and tamoxifen-plus-metformin groups but not in single-agent groups; amplification failed in several lanes and the panels do not separate treatments. - Authors conclude the direction of metformin’s effect on **ESR1** splicing depends on culture density and does not hold up in a dose-response test at high density; they judge HMGA1a unlikely to be the main mediator. - The source did not report detailed experimental protocols for seeding densities, exact exposure schedules for every assay beyond 24–48 h windows, nor precise sample sizes or statistical analyses in the abstract.
## Clinical Analysis & Structured Key Points
Metformin lowers HMGA1a and RBM3 protein in breast cancer cells, and its effect on ESR1 splicing depends on cell density and exposure time | bioRxiv Skip to main content New Results Metformin lowers HMGA1a and RBM3 protein in breast cancer cells, and its effect on ESR1 splicing depends on cell density and exposure time Yoshihiro Harada , Tomoko Tanaka , Yuriko Hamaguchi , Yuta Horita , Hiroyoshi Harada , Masayoshi Mori , Yusuke Murata , View ORCID Profile Kenji Ohe doi: https://doi.org/10.64898/2026.11.04.764423 Yoshihiro Harada 1 Faculty of Pharmaceutical Sciences, Fukuoka University,; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Tomoko Tanaka 2 Faculty of Medicine, Fukuoka University Find this author on Google Scholar Find this author on PubMed Search for this author on this site Yuriko Hamaguchi 2 Faculty of Medicine, Fukuoka University Find this author on Google Scholar Find this author on PubMed Search for this author on this site Yuta Horita 1 Faculty of Pharmaceutical Sciences, Fukuoka University,; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Hiroyoshi Harada 1 Faculty of Pharmaceutical Sciences, Fukuoka University,; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Masayoshi Mori 1 Faculty of Pharmaceutical Sciences, Fukuoka University,; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Yusuke Murata 1 Faculty of Pharmaceutical Sciences, Fukuoka University,; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kenji Ohe 1 Faculty of Pharmaceutical Sciences, Fukuoka University,; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Kenji Ohe For correspondence: ohekenji{at}fukuoka-u.ac.jp Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract The ESR1 gene produces ERα46, an N-terminally truncated isoform generated by skipping of exon 1, which is reduced in tamoxifen-resistant breast cancer cells. We have reported that metformin moves the ratio of full-length ERα to ERα46 in opposite directions in MCF-7 cells and their tamoxifen-resistant subline TAMR1, and that metformin reduces TAMR1 xenograft growth (Harada et al., Am J Pharm Health Res 2022;10(11)). That report leaves two questions open: whether the effect is dosedependent and stable across culture conditions, and what splicing factor might carry it. Here we report the experiments that bear on both. Across a full dose range from 0.25 to 5 mM at high seeding density, metformin produced no consistent change in the full-length share of ESR1 transcript in either line: densitometry of the gel gave 42%, 43%, 42%, 43%, 45% and 48% in MCF-7 cells and 55%, 44%, 52%, 47%, 68% and 43% in TAMR1 cells. The reported shift therefore depends on the seeding density used, and the comparison that produced it is not reproduced at high density. At low density the MCF-7 response persisted to 48 h (52%, 62% and 68% at 0, 2.5 and 5 mM). Metformin lowered HMGA1a protein in MCF-7 cells and showed the same tendency in TAMR1 cells, at both seeding densities, and lowered RBM3 protein in TAMR1 cells at 24 and 48 h. HMGA1a is the factor we previously showed to generate ERα46 by trapping U1 snRNP at an upstream pseudo-5′ splice site, so a fall in HMGA1a predicts less ERα46, the opposite of what was seen in TAMR1 cells at low density. The fall in RBM3, the protein through which metformin alters splicing in myotonic dystrophy, is the more plausible candidate. RT-PCR of the xenograft tumours from the earlier study detected full-length ESR1 transcript in the untreated and tamoxifen-plus-metformin groups but not in the singleagent groups, with amplification failing in several lanes; these panels do not separate the treatments. Taken together, the direction of the metformin effect on ESR1 splicing is conditional on culture density and does not survive a dose-response test at high density, and HMGA1a is unlikely to be the factor that carries it. Competing Interest Statement The authors have declared no competing interest. Footnotes https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE249290 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69845 Funder Information Declared Ministry of Education, Culture, Sports, Science and Technology (MEXT) / JSPS KAKENHI , 18K09212 MEXT / JSPS KAKENHI , 15H05721 Fukuoka University（Suisyo Kenkyu Project&#65289, ;0 , 167005 , 197010 Center for Clinical and Translational Research, Kyushu University Hospital , A147 Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Back to top Previous Next Posted November 05, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Metformin lowers HMGA1a and RBM3 protein in breast cancer cells, and its effect on ESR1 splicing depends on cell density and exposure time Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Metformin lowers HMGA1a and RBM3 protein in breast cancer cells, and its effect on ESR1 splicing depends on cell density and exposure time Yoshihiro Harada , Tomoko Tanaka , Yuriko Hamaguchi , Yuta Horita , Hiroyoshi Harada , Masayoshi Mori , Yusuke Murata , Kenji Ohe bioRxiv 2026.11.04.764423; doi: https://doi.org/10.64898/2026.11.04.764423 Share This Article: Copy Citation Tools Metformin lowers HMGA1a and RBM3 protein in breast cancer cells, and its effect on ESR1 splicing depends on cell density and exposure time Yoshihiro Harada , Tomoko Tanaka , Yuriko Hamaguchi , Yuta Horita , Hiroyoshi Harada , Masayoshi Mori , Yusuke Murata , Kenji Ohe bioRxiv 2026.11.04.764423; doi: https://doi.org/10.64898/2026.11.04.764423 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Animal Behavior and Cognition (8164) Biochemistry (19027) Bioengineering (15171) Bioinformatics (45723) Biophysics (22958) Cancer Biology (20235) Cell Biology (27478) Clinical Trials (138) Developmental Biology (14217) Ecology (21515) Epidemiology (2067) Evolutionary Biology (25911) Genetics (16429) Genomics (23952) Immunology (19153) Microbiology (43443) Molecular Biology (18459) Neuroscience (95730) Paleontology (717) Pathology (3059) Pharmacology and Toxicology (5247) Physiology (8329) Plant Biology (16368) Scientific Communication and Education (2122) Synthetic Biology (4673) Systems Biology (10444) Zoology (2436)
## Related Clinical Research

- [Metformin use and incident breast cancer risk: time-bias–aware meta-analysis and limits for imegli](https://medichelpline.com/clinical-feed/medrxiv-8-metformin-use-and-the-risk-of-incident-breast-cancer-a-systematic-review-and.md)
- [Gum acacia–gelatin nanohydrogel co-delivering metformin and doxorubicin inhibits TNT-driven breast](https://medichelpline.com/clinical-feed/pubmed-42605874.md) (DOI: 10.1039/d6bm00697c)
- [Targeting VISTA for Skin Cancer Immunotherapy: Source Article Not Available](https://medichelpline.com/clinical-feed/frontiers-in-immunology-17-targeting-vista-as-a-novel-immunotherapy-for-skin-cancer.md)
- [Captivity and Cross-Fostering Reshape Gut Microbiota in Wild Wood Mice](https://medichelpline.com/clinical-feed/biorxiv-12-wild-wood-mouse-gut-microbiota-are-influenced-by-captivity-and-cross-fostering.md)
- [High-Fiber Diet Outperforms Metformin in Blood Sugar Control and Weight Loss](https://medichelpline.com/clinical-feed/medical-news-today-0-high-fiber-diet-vs-metformin-which-is-better-for-blood-sugar-control-weight-loss.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.